Results 31 to 40 of about 23,486 (164)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa

Clinical and Applied Thrombosis/Hemostasis, 2020
Andexanet alfa is a recombinant factor Xa decoy protein, designed to reverse bleeding associated with oral anti-Xa agents. Andexanet alfa is also reported to neutralize the effects of heparin-related drugs.
Fakiha Siddiqui BDS, Alfonso Tafur MD, Emily Bontekoe BS, Omer Iqbal MD, Walter Jeske PhD, Siddharth Mehrotra, Debra Hoppensteadt PhD, Eduardo Ramacciotti MD, PhD, Jawed Fareed PhD   +8 more
doaj   +1 more source

Choosing Between Enoxaparin and Fondaparinux for the Prevention of Thromboembolism: A Meta-Analysis of Randomized Trials

Egyptian Journal of Critical Care Medicine, 2022
Background Venous thromboembolism (VTE), are few of the most serious complications in ICU. There are Pharmacological and mechanical prophylaxis methods are used to reduce the risk of thromboembolism and the most efficient is the pharmacological methods ...
Enas W. Mahdy, Ahmed Mostafa Abd El-Hamid, Reham Mahmoud Shady, Basem Mofreh Aglan   +3 more
doaj   +1 more source

Low-Molecular-Weight Heparins (LMWH) and Synthetic Factor X Inhibitors Can Impair the Osseointegration Process of a Titanium Implant in an Interventional Animal Study

Medicina, 2022
Background and objectives: Cementless total hip arthroplasty is a common surgical procedure and perioperative thromboprophylaxis is used to prevent deep vein thrombosis or pulmonary embolism.
Dragos Apostu, Bianca Berechet, Daniel Oltean-Dan, Alexandru Mester, Bobe Petrushev, Catalin Popa, Madalina Luciana Gherman, Adrian Bogdan Tigu, Ciprian Ionut Tomuleasa, Lucian Barbu-Tudoran, Horea Rares Ciprian Benea, Doina Piciu   +11 more
doaj   +1 more source

Pathogenic PF4/Polyanion ELISA‐Negative Antibodies in HIT

American Journal of Hematology, Volume 101, Issue 8, Page 1790-1798, August 2026.
ABSTRACT Background Platelet factor 4‐polyanion enzyme‐linked immunosorbent assays (ELISAs) are considered highly sensitive for diagnosing heparin‐induced thrombocytopenia (HIT), such that current practice guidelines recommend use of ELISA‐negative results to exclude HIT.
Adam J. Kanack, Noah P. Splinter, Emily E. Mauch, Leben Tefera, Morayma Reyes Gil, Sakshi Jasra, Andrew Goodwin, Kristi J. Smock, Hadiyah Ahmad, Aneel Ashrani, Nathaniel L. Robinson, Ana I. Casanegra, Curtis G. Jones, Shannon M. Pechauer, Erin Yttre, Richard H. Aster, Mindy C. Kohlhagen, Rachel R. Leger, Gretchen Johns, David L. Murray, Lu Zhou, Demin Wang, Renren Wen, Dong Chen, Rajiv K. Pruthi, Anand Padmanabhan   +25 more
wiley   +1 more source

An Italian cartography of VEXAS‐related thrombosis

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract Thrombotic events (TEs) occur in up to 40% of patients with vacuoles, E1 enzyme, X‐linked, autoinflammatory, and somatic (VEXAS) syndrome, but data on its clinical‐genomics features and anticoagulation strategies are limited. To gain more insight into this, we conducted a two‐step study evaluating the prevalence and outcome of TE in VEXAS ...
Giorgia Ranucci, Maria Rosaria Pascale, Vittorio Forte, Elisa Diral, Corrado Campochiaro, Jacqueline Ferrari, Mariachiara Cuccaro, Chiara Cattaneo, Francesca Crisafulli, Lucia Cardillo, Valeria Renola, Elisa Meddi, Marianna Velocci, Elisa Casciani, Francesca Romano, Pellegrino Musto, Serafina Barbato, Giorgia Battipaglia, Marco Frigeni, Erika Morsia, Arianna Savi, Cristina Papayannidis, Elena Crisà, Laura Cicconi, Isabella Capodanno, Alfonso Fiumarella, Antonio Pierini, Massimo Breccia, Giovanni Orsolini, Giulia Rivoli, Sara Bindoli, Davide Firinu, Antonio Vitale, Bruno Fattizzo, Monica Bocchia, Luca Cantarini, Chiara Pinton, Gabriele Todisco, Nicola Toschi, Paola Triggianese, Adriano Venditti, Maria Teresa Voso, Carmelo Gurnari   +42 more
wiley   +1 more source

Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies

Vascular Health and Risk Management, 2010
François SchieleDepartment of Cardiology, University Hospital Jean-Minjoz, Besançon, FranceAbstract: Anticoagulant therapy is a major component in the management of acute coronary syndromes (ACS).
François Schiele
doaj  

Fondaparinux Sodium Compared With Low‐Molecular‐Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta‐analysis

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Fondaparinux sodium has been compared with low‐molecular‐weight heparins (LMWH) in randomized controlled trials for perioperative surgical thromboprophylaxis.
Arun Kumar, Ashna Talwar, Joel F. Farley, Jagannath Muzumdar, Jon C. Schommer, Rajesh Balkrishnan, Wenchen Wu   +6 more
doaj   +1 more source

Factor XI Inhibition for Ischemic Stroke Secondary Prevention: Pharmacology, Clinical Evidence, and Future Directions

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Ischemic stroke remains a leading cause of death and disability worldwide, and bleeding (particularly intracranial hemorrhage) continues to limit conventional antithrombotic therapy in secondary prevention, even with direct oral anticoagulants.
Federica Ferrari, Roberto Federico Villa
wiley   +1 more source

Estimated impact of model‐guided venous thromboembolism prophylaxis versus real‐world practice

Journal of Hospital Medicine, Volume 21, Issue 8, Page 845-853, August 2026.
Abstract Background The American Society of Hematology (ASH) recommends assessing venous thromboembolism (VTE) and major bleeding risk to optimize pharmacological VTE prophylaxis for medical inpatients. However, the clinical utility of model‐guided approaches remains unknown.
Benjamin G Mittman, Michael B. Rothberg
wiley   +1 more source

Advances in Chemical Synthesis of Fondaparinux

Journal of Chemistry, 2019
Fondaparinux (trade name Arixtra) is a safe and efficacious anticoagulant, and it is chemically related to low-molecular-weight heparins such as enoxaparin. Fondaparinux is a synthetic pentasaccharide, and its synthesis is difficult and expensive.
Yili Ding, Chamakura V. N. S. Vara Prasad, Bingyun Wang   +2 more
doaj   +1 more source